Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM5WCV4)

Drug Name
JX-594 Drug Info
Synonyms Pexastimogene devacirepvec
Indication
Disease Entry ICD 11 Status REF
Hepatocellular carcinoma 2C12.02 Phase 3 [1]
Colorectal cancer 2B91.Z Phase 2 [2]
Liver cancer 2C12 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DM5WCV4

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Granulocyte-macrophage colony-stimulating factor (CSF2) TTNYZG2 CSF2_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Granulocyte-macrophage colony-stimulating factor (CSF2) DTT CSF2 3.027 3.863 3.372 4.747
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hepatocellular carcinoma
ICD Disease Classification 2C12.02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Granulocyte-macrophage colony-stimulating factor (CSF2) DTT CSF2 4.07E-03 0.26 1.2
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02017678) Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin. U.S. National Institutes of Health.
3 Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70.